Stock · GLENMARK · Healthcare
GLENMARK share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for Glenmark Pharmaceuticals Limited, refreshed every end-of-day run. A systematic, data-only read on Glenmark Pharmaceuticals Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads GLENMARK as constructive with a Crack Score of 82/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where GLENMARK stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
33/100Money flow
51/100Result pulse · Q4 FY26
0/100Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
ATR contracting (volatility dry-up)
coiling 1-12% under 52w high
holding above 50DMA
above 200DMA
Red flags
above 200DMA (not a confirmed short-side trend)
weak filed result (score 0.0)
Relative valuation
P/E (TTM)
46.5P/E vs sector
+0.9%Sector percentile
47PEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for GLENMARK are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the GLENMARK chart, refreshed every end-of-day run.
The Crack Score, and how it is built82 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for GLENMARK, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on GLENMARK reads right now.
The editorial price read on GLENMARK is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on GLENMARK can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving GLENMARK.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why GLENMARK moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
Glenmark Pharmaceuticals Limited's most recent quarter, parsed straight from the official BSE filing. Every figure links back to its primary source.
Result Pulse
0 / 100Revenue
Rs 3,771 crNet profit
Rs 301 crEPS (quarter)
Rs 10.68| Growth | YoY | QoQ |
|---|---|---|
| Revenue | n/a | n/a |
| Net profit | n/a | n/a |
| Net margin | n/a | |
Figures are the Q4 FY26 result for Glenmark Pharmaceuticals Limited, parsed straight from the official BSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
Glenmark Pharmaceuticals Limited's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
GLENMARK official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 3,771 cr | Rs 10.68 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 3,901 cr | Rs 14.29 | n/a | 40/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 6,047 cr | Rs 21.63 | n/a | 60/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 3,264 cr | Rs 1.66 | n/a | 50/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 3,256 cr | Rs 0.16 | n/a | 50/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 3,388 cr | Rs 12.33 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 3,434 cr | Rs 12.55 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 3,244 cr | Rs 12.06 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 3,063 cr | Rs -43.18 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 2,507 cr | Rs -12.45 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 3,207 cr | Rs -2.90 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 3,402 cr | Rs 5.31 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 3,374 cr | Rs -15.18 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 3,464 cr | Rs 9.66 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 3,375 cr | Rs 9.23 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 2,777 cr | Rs 6.82 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 3,019 cr | Rs 5.51 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 3,173 cr | Rs 7.86 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 3,147 cr | Rs 9.74 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 2,965 cr | Rs 10.86 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 2,860 cr | Rs 8.29 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 2,787 cr | Rs 8.80 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 2,952 cr | Rs 8.29 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 2,345 cr | Rs 9.00 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 2,767 cr | Rs 7.81 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 2,736 cr | Rs 13.52 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 2,815 cr | Rs 9.06 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 2,323 cr | Rs 3.87 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 2,563 cr | Rs 5.73 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Consolidated, audited | Rs 2,555 cr | Rs 4.12 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 2,581 cr | Rs 14.67 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Consolidated, audited | Rs 2,166 cr | Rs 8.26 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
Glenmark Pharmaceuticals Limited's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
16,983 crNet profit (TTM)
1,362 crEBIT (TTM)
2,193 crProfit before tax (TTM)
1,985 crNet margin (TTM)
8.0%Finance costs (TTM)
209 crBalance sheet, as filed 2026-03-31
Total assets
19,908 crShareholder equity
10,512 crTotal borrowings
0.0 crCash and equivalents
1,175 crInventory
3,431 crTrade receivables
4,963 crThe cash engine, latest filed year
Operating cash flow
3,445 crCapex
1,358 crFree cash flow
2,087 crInvesting flow
1,283 crFinancing flow
2,709 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 16,983 cr | 1,362 cr | 10,512 cr | 0.0 cr | 3,445 cr |
| FY25 | 13,322 cr | 1,047 cr | 8,849 cr | 2,194 cr | -828 cr |
| FY24 | 11,813 cr | -1,434 cr | 7,848 cr | 991 cr | -265 cr |
| FY23 | 12,990 cr | 377 cr | 9,839 cr | 4,348 cr | 625 cr |
| FY22 | 12,305 cr | 994 cr | 9,438 cr | 3,670 cr | 1,109 cr |
| FY21 | 10,944 cr | 970 cr | 7,064 cr | 4,402 cr | n/a |
Every figure is parsed from Glenmark Pharmaceuticals Limited's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record17 earnings calls
Every GLENMARK earnings call BazaarBaazi has indexed, latest 28 Feb 2026. Read management in its own words, straight from the filed transcript.
Glenmark Pharmaceuticals Limited earnings calls on record
17 calls since 31 May 2022
Show 9 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed1 disclosure
Every recent official filing from Glenmark Pharmaceuticals Limited, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
Glenmark Pharmaceuticals Limited's most recent official filing is a Earnings dated 31 Mar 2026.
Event Heat
61 / 100Glenmark Pharmaceuticals Limited Q4 FY26 earnings result: sales_acceleration
Event Heat is a dated net read of Glenmark Pharmaceuticals Limited's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the GLENMARK chart. Not a substitute for a registered research note.
| Ticker | GLENMARK |
|---|---|
| Full name | Glenmark Pharmaceuticals Limited |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE935A01035 |
| Market-cap band | ~63,257 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | GLENMARK |
Reference chartLevels in show
The daily frame the desk reads on GLENMARK.
FAQ11 reader questions · AEO-eligible
The line on GLENMARK, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the GLENMARK share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on GLENMARK. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for GLENMARK?
The BazaarBaazi Crack Score for GLENMARK is 82 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on GLENMARK?
Strike-level option inventory for GLENMARK is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is GLENMARK in and which peers does BazaarBaazi track?
GLENMARK sits in Healthcare (mid cap), indicative market cap ~63,257 cr (indicative), ISIN INE935A01035. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on Glenmark Pharmaceuticals Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the GLENMARK view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on GLENMARK is bullish, published in Systematic Read on 21 Jul 2026.
Is GLENMARK a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, Glenmark Pharmaceuticals Limited sits in the Scanned tier with a setup score of 67/100 (technical 100, fundamental 33). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read Glenmark Pharmaceuticals Limited's earnings call transcripts?
BazaarBaazi indexes 17 GLENMARK earnings calls going back to 2022-05-31, latest 2026-02-28. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was Glenmark Pharmaceuticals Limited's Q4 FY26 net profit?
Glenmark Pharmaceuticals Limited reported a net profit of Rs 301 cr for Q4 FY26 (the quarter ended 31 March 2026). The figure is from the company's official NSE filing.
What was Glenmark Pharmaceuticals Limited's Q4 FY26 revenue?
Glenmark Pharmaceuticals Limited reported revenue of Rs 3,771 cr for Q4 FY26. The figure is from the company's official NSE filing.
How does BazaarBaazi rate Glenmark Pharmaceuticals Limited's Q4 FY26 result?
BazaarBaazi gives Glenmark Pharmaceuticals Limited's Q4 FY26 result a Result Pulse of 0 out of 100, with a verdict of Insufficient data. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Glenmark Pharmaceuticals Ltd announced recently?
The most recent official filing on record for Glenmark Pharmaceuticals Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside GLENMARK, each a living view refreshed every end-of-day run.